Maryland-based biotechnology company, Novavax, said on Tuesday its experimental COVID-19 vaccine produced antibodies against the novel coronavirus and appears to be safe, according to an early-stage study.
President of Research and Development, Dr. Gregory Glenn told Reuters the experimental vaccine “looked good in animals.
Now it looks really good in people."